Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Inclusion Criteria: * Histologically or cytologically confirmed malignant salivary gland tumor (MSGT), including one of the following histologic subtypes: * Adenoid cystic carcinoma (ACC) with c v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (Kit) overexpression or non-ACC MSGT that is not amenable to potentially curable surgery or radiation * c-KIT overexpression in ACC patients is defined as cluster of differentiation (CD) 117 staining by immunohistochemistry (IHC) in 25% of tumor cells * No stipulation for c-KIT overexpression is not required for non-ACC MSGT patients * Patients must have radiographically measurable disease; radiographically measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral computed tomography (CT) scan * Patients must have evidence of disease progression (objective growth of existing tumors) within 4 months of study entry * No known brain metastases, unless patient meets both of the following criteria: * Neurologic status stable for \>= 8 weeks after completion of definitive local therapy (surgery or radiotherapy) * No neurologic dysfunction that would confound study results * Life expectancy greater than 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 OR Karnofsky performance status (PS) \>= 60% * Leukocytes \>= 3,000/mcL * Absolute…